Dr. Burkhard Blank brings to Oryon more than 25 years of broad managerial experience and global drug development across all clinical, medical, and regulatory disciplines in multiple disease areas. He has deep knowledge in both early and late-stage clinical development and has been instrumental in several NDA and MAA submissions for small molecules, biologics, and drug-device combinations.
Dr. Blank recently served as CMO/Head of R&D at MannKind Corporation after serving for six years in the same position at Acorda Therapeutics. While at Acorda, he oversaw the Phase 3 development in North America and in Europe for Inbrija® (levodopa inhalation powder) for Parkinson’s disease with subsequent one-cycle approvals by the FDA and the EMA.
Earlier in his career, Dr. Blank spent 20 years at Boehringer Ingelheim, serving in progressive leadership roles, including the CMO position in the US. Under his guidance, four products received approval including Mirapex® (for Parkinson’s disease) and Spiriva® (for COPD) for which he oversaw the development and led the presentation at the FDA advisory committee meeting.
Dr. Blank received his medical degree from Universitaet Marburg, Germany, and is board-certified in internal medicine.
